Ranibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration: 12 months of retreatment and vision outcomes from a randomized study.

Katja Hatz,U. Schneider,Paul B. Henrich,B. Braun,Stefan Sacu,Christian Prünte

Ranibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration: 12 months of retreatment and vision outcomes from a randomized study.

2014

Katja Hatz
U. Schneider
Paul B. Henrich
B. Braun
Stefan Sacu
Christian Prünte

Purpose: To investigate the injection frequency and visual acuity (VA) outcomes with combination therapy (ranibizumab plus verteporfin photodynamic therapy, PDT)

Keywords:

Ranibizumab
Macular degeneration
Randomized controlled trial
Ophthalmology
Verteporfin
Combined Modality Therapy
Pathology
Visual acuity
Combination therapy
Photodynamic therapy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations